| Orelabrutinib versus chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trial.PMID 42402625 · Signal Transduct Target Ther |
2026-Jul-06 |
2 | 3 | 3 | 6 |
提取完成 |
| First-line pembrolizumab plus chemotherapy versus chemotherapy alone for advanced esophageal cancer: 5-year extended follow-up in the Japanese subgroup of KEYNOTE-590.PMID 42047965 · Esophagus |
2026-Jul |
2 | 3 | 3 | 6 |
提取完成 |
| First-line atezolizumab monotherapy vs . single-agent chemotherapy in patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum-based therapy: Analysis of the IPSOS Asian subpopulation.PMID 41424028 · Chin Med J (Engl) |
2026-Jun-20 |
2 | 2 | 2 | 4 |
提取完成 |
| Computationally Derived Spatial Immune Signature Identifies Trastuzumab Responders in HER2+ Breast Cancer: NSABP B-41 Clinical Trial Validation.PMID 41915435 · Clin Cancer Res |
2026-Jun-15 |
1 | 4 | 4 | 6 |
质量警告 |
| Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial.PMID 41770817 · Blood |
2026-Jun-11 |
1 | 1 | 1 | 2 |
提取完成 |
| HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer.PMID 41369677 · J Clin Oncol |
2026-Jun-10 |
5 | 7 | 7 | 8 |
质量警告 |
| Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma: dynamics of MRD negativity in the IMROZ study.PMID 41758929 · Blood |
2026-Jun-04 |
2 | 3 | 3 | 6 |
提取完成 |
| Factors Associated With Primary Site Local Therapy in Patients With Nonmetastatic Ewing Sarcoma Treated With Interval-Compressed Chemotherapy: A Report From the Children's Oncology Group.PMID 41285272 · Int J Radiat Oncol Biol Phys |
2026-Jun-01 |
1 | 4 | 4 | 7 |
质量警告 |
| Phase III Trial of Pegylated Liposomal Doxorubicin for Patients with Advanced and Refractory Desmoid Tumors.PMID 41504634 · Clin Cancer Res |
2026-Jun-01 |
1 | 1 | 1 | 2 |
提取完成 |
| Framework for Statistical Parametric Mapping of the Interactions between Glioblastoma Location, Treatment, Prognostic Variables, and Survival Using a Phase III Trial.PMID 41837753 · Clin Cancer Res |
2026-Jun-01 |
5 | 11 | 11 | 31 |
质量警告 |
| Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial.PMID 42060297 · JAMA Oncol |
2026-Jun-01 |
1 | 2 | 2 | 4 |
提取完成 |
| Adjuvant Chemoradiotherapy or Chemotherapy After D2 Gastrectomy in Gastric Cancer: A Randomized Clinical Trial.PMID 42295761 · JAMA Netw Open |
2026-Jun-01 |
2 | 2 | 2 | 3 |
质量警告 |
| Optimal Timing of Surgery Following Neoadjuvant Therapy for Surgical and Oncological Outcomes in Advanced Esophageal Squamous Cell Carcinoma: An Exploratory Analysis of JCOG1109.PMID 41535566 · Ann Surg Oncol |
2026-Jun |
3 | 8 | 8 | 26 |
质量警告 |
| Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.PMID 41896648 · Nat Med |
2026-Jun |
1 | 2 | 2 | 4 |
提取完成 |
| Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trial.PMID 42168151 · Signal Transduct Target Ther |
2026-May-22 |
2 | 3 | 3 | 5 |
质量警告 |
| Randomized Phase II/III Trial Comparing Hepatectomy, Followed by mFOLFOX6 With Hepatectomy Alone for Liver Metastasis From Colorectal Cancer: Long-Term Results of JCOG0603.PMID 41564372 · J Clin Oncol |
2026-May-20 |
2 | 8 | 8 | 16 |
提取完成 |
| Five-year outcomes of pembrolizumab versus chemotherapy in Chinese patients with non-small-cell lung cancer and programmed cell death ligand 1 tumor proportion score ≥1%: KEYNOTE-042 China study.PMID 41474069 · Int J Cancer |
2026-May-01 |
1 | 4 | 4 | 8 |
提取完成 |
| Long-Term Performance of Prognostic Models for Advanced Renal Cell Carcinoma in the Era of Improved Survival With Immune Checkpoint Inhibitors.PMID 40658913 · JCO Oncol Pract |
2026-May |
1 | 1 | 1 | 3 |
提取完成 |
| Belantamab mafodotin, pomalidomide, and dexamethasone in Japanese patients with RRMM in the phase 3 DREAMM-8 trial.PMID 41493718 · Int J Hematol |
2026-May |
1 | 1 | 1 | 1 |
质量警告 |
| The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B-Cell Lymphoma (CLSG-CNS-01): A Randomized, Multicenter, Prospective Phase 3 Trial.PMID 42062177 · Hematol Oncol |
2026-May |
1 | 2 | 2 | 5 |
质量警告 |
| CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.PMID 41628350 · Blood Adv |
2026-Apr-28 |
4 | 8 | 8 | 18 |
质量警告 |
| VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.PMID 41802242 · J Clin Oncol |
2026-Apr-20 |
2 | 4 | 4 | 8 |
提取完成 |
| FDA Approval Summary: Durvalumab for the Treatment of Adult Patients with Muscle-Invasive Bladder Cancer.PMID 41678313 · Clin Cancer Res |
2026-Apr-15 |
2 | 2 | 2 | 3 |
质量警告 |
| STRATEGIC-1: multiple-line, randomized, open-label GERCOR-PRODIGE-39 phase III trial in unresectable RAS/BRAF wild-type metastatic colorectal cancer.PMID 41980919 · Signal Transduct Target Ther |
2026-Apr-14 |
1 | 2 | 2 | 4 |
提取完成 |
| Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial.PMID 41968137 · Signal Transduct Target Ther |
2026-Apr-13 |
2 | 5 | 4 | 7 |
部分完成 |
| A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.PMID 41490515 · Blood |
2026-Apr-09 |
2 | 11 | 11 | 20 |
质量警告 |
| Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study.PMID 41946687 · Signal Transduct Target Ther |
2026-Apr-08 |
2 | 2 | 2 | 3 |
质量警告 |
| Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma.PMID 41537702 · Clin Cancer Res |
2026-Apr-01 |
4 | 13 | 13 | 63 |
质量警告 |
| Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Phase 3 Trials.PMID 39542826 · Eur Urol Oncol |
2026-Apr |
2 | 8 | 8 | 14 |
质量警告 |
| Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points.PMID 41349040 · J Urol |
2026-Apr |
1 | 2 | 2 | 4 |
提取完成 |